{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:01Z","timestamp":1793806141341,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      We aimed to investigate serum levels of FAM19A5, a novel adipokine implicated in inflammation and metabolic regulation, and to examine its association with key metabolic and inflammatory markers in individuals newly diagnosed with type 2 diabetes mellitus (T2DM). This case-control study included 54 patients with newly diagnosed T2DM and 54 age- and sex-matched normoglycemic controls aged 35 to 65 years. Continuous variables were summarized according to their distributions and compared using the independent-samples\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      test or Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      test, as appropriate. Spearman rank correlation was used to examine associations in the pooled sample, with false discovery rate correction for multiple testing. Subgroup analyses were conducted by metabolic syndrome, insulin resistance, and body mass index (BMI) category. The incremental value of FAM19A5 beyond conventional markers was explored using multivariable logistic regression and DeLong comparisons of the areas under the curve (AUCs). Serum FAM19A5 was lower in the T2DM group than in controls (376.1 [312.1\u2013577.6] vs 554.5 [365.6\u20131524.2] ng\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). In the pooled sample, FAM19A5 was inversely correlated with fasting glucose (\u03c1 = \u22120.266,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .005), 2-hour oral glucose tolerance test (\u03c1 = \u22120.308,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001), and HbA1c (\u03c1 = \u22120.212,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .028), but not with BMI, waist circumference, lipid parameters, homeostasis model assessment of insulin resistance (HOMA-IR), or high-sensitivity C-reactive protein (hs-CRP). After false discovery rate correction, the associations with fasting and 2-hour oral glucose tolerance test remained significant. Within the T2DM group, FAM19A5 was lower in patients with metabolic syndrome (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .004), insulin resistance (HOMA-IR &gt; 2.71;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .023), or BMI \u226525 kg\/m\u00b2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .021). FAM19A5 alone showed poor discrimination for T2DM (AUC: 0.684; sensitivity: 66.7%; specificity: 53.7%). Adding FAM19A5 to a model containing BMI, HOMA-IR, and hs-CRP improved model fit (likelihood-ratio \u03c7\u00b2 = 13.1,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) but not discrimination (AUC: 0.920 vs 0.943; DeLong\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .154). Serum FAM19A5 levels were lower in newly diagnosed T2DM and remained independently associated with diabetes status after adjustment for BMI, HOMA-IR, and hs-CRP. Correlations with glycemic measures were weak, and FAM19A5 alone had poor discriminatory performance. These findings support further investigation of FAM19A5 as a molecule of potential mechanistic interest, but not as a clinically useful diagnostic biomarker. Larger longitudinal studies are needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050782","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:01:07Z","timestamp":1790359267000},"page":"e50782","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Serum FAM19A5 in newly diagnosed type 2 diabetes mellitus and its association with metabolic and inflammatory parameters"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-7571","authenticated-orcid":false,"given":"Halime Seda","family":"K\u00fc\u00e7\u00fckerdem","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Izmir Health Sciences University, Bozyaka Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giray","family":"Bozkaya","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Izmir Health Sciences University, Bozyaka Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izmir Health Sciences University, Bozyaka Training and Research Hospital, Izmir, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10654-022-00960-8","article-title":"Estimates and forecasts on the burden of prediabetes and diabetes in adult and elderly population in T\u00fcrkiye.","volume":"38","author":"Satman","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes.","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"R4-20261104","first-page":"155","article-title":"Adipoz doku ve adipoz dokudan salgilanan bazi proteinler.","volume":"5","author":"Demirci","year":"2017","journal-title":"MAK\u00dc Sag Bil Enst Derg"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1748-1716.2010.02216.x","article-title":"Cross-talk between adipose tissue and vasculature: role of adiponectin.","volume":"203","author":"Li","year":"2011","journal-title":"Acta Physiol (Oxf)"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jcb.24402","article-title":"Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus.","volume":"114","author":"Akash","year":"2013","journal-title":"J Cell Biochem"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12950-018-0185-8","article-title":"The role of adipokines in skeletal muscle inflammation and insulin sensitivity.","volume":"15","author":"Nicholson","year":"2018","journal-title":"J Inflamm (Lond)"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fendo.2013.00105","article-title":"RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication.","volume":"4","author":"Yamamoto","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.117.032398","article-title":"Novel adipokine, FAM19A5, inhibits neointima formation after injury through sphingosine-1-phosphate receptor 2.","volume":"138","author":"Wang","year":"2018","journal-title":"Circulation"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/DMSO.S460226","article-title":"Can adipokine FAM19A5 be a biomarker of metabolic disorders?","volume":"17","author":"Weso\u0142ek-Leszczy\u0144ska","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.33854\/heme.v5i3.1287","article-title":"Peranan protein circulating FAM19A5 sebagai faktor ateroprotektif terhadap proliferasi dan migrasi vascular smooth muscle cell.","volume":"5","author":"Adelin","year":"2023","journal-title":"Health Med J"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/1479164119860746","article-title":"Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes.","volume":"16","author":"Lee","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2022.03.011","article-title":"Circulating FAM19A5 level is associated with the presence and severity of coronary artery disease.","volume":"354","author":"Ma","year":"2022","journal-title":"Int J Cardiol"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/CIRCULATIONAHA.118.034454","article-title":"Understanding obesity-related cardiovascular disease: it\u2019s all about balance.","volume":"138","author":"Zarzour","year":"2018","journal-title":"Circulation"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbi.2020.03.021","article-title":"Serum FAM19A5 levels: a novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder.","volume":"87","author":"Han","year":"2020","journal-title":"Brain Behav Immun"},{"key":"R16-20261104","first-page":"548","article-title":"Population health screenings for the prevention of chronic disease progression.","volume":"25","author":"Fragala","year":"2019","journal-title":"Am J Manag Care"},{"issue":"suppl 1","key":"R17-20261104","first-page":"S17","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes: 2022.","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"1 suppl","key":"R19-20261104","first-page":"2","article-title":"The national cholesterol education program adult treatment panel III guidelines.","volume":"9","author":"Lipsy","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1472-6823-13-47","article-title":"Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study.","volume":"13","author":"Gayoso-Diz","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve.","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12902-021-00820-8","article-title":"Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease.","volume":"21","author":"Yari","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000524624","article-title":"Follistatin-like 1 and family with sequence similarity to 19 member A5 levels are decreased in obese children and associated with glucose metabolism.","volume":"78","author":"Xie","year":"2022","journal-title":"Ann Nutr Metab"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:00:38Z","timestamp":1793804438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050782"}},"subtitle":["A case-control study"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":25,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050782","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}